MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Search

REVOLUTION Medicines Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

38.35 1.19

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

37.92

Max

38.92

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-19M

-213M

Pelnas, tenkantis vienai akcijai

-1.13

Pelno marža

-74.379

Darbuotojai

616

EBITDA

-24M

-237M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+86.43% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-754M

6.8B

Ankstesnė atidarymo kaina

37.16

Ankstesnė uždarymo kaina

38.35

Naujienos nuotaikos

By Acuity

50%

50%

148 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-14 22:07; UTC

Pagrindinės rinkos jėgos

Trade Desk Rises on S&P 500 Inclusion

2025-07-14 17:06; UTC

Pagrindinės rinkos jėgos

Crypto Assets Rally Ahead of Possible U.S. Legislation

2025-07-14 16:47; UTC

Įsigijimai, susijungimai, perėmimai

NatWest to Sell Stake in Permanent TSB

2025-07-14 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-07-14 23:38; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

2025-07-14 23:37; UTC

Rinkos pokalbiai

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

2025-07-14 23:29; UTC

Rinkos pokalbiai

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

2025-07-14 23:29; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-07-14 23:02; UTC

Uždarbis

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

2025-07-14 23:02; UTC

Uždarbis

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

2025-07-14 23:02; UTC

Uždarbis

China Vanke 1H Loss Was CNY9.85B >000002.SZ

2025-07-14 23:01; UTC

Uždarbis

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

2025-07-14 23:01; UTC

Uždarbis

China Vanke Expects 1H Loss to Widen >000002.SZ

2025-07-14 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-14 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-14 20:07; UTC

Rinkos pokalbiai

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

2025-07-14 20:05; UTC

Rinkos pokalbiai

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

2025-07-14 19:11; UTC

Rinkos pokalbiai

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

2025-07-14 19:09; UTC

Rinkos pokalbiai

Gold Breaks a 3-Day Win Streak -- Market Talk

2025-07-14 18:59; UTC

Rinkos pokalbiai

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

2025-07-14 18:30; UTC

Įsigijimai, susijungimai, perėmimai

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

2025-07-14 18:25; UTC

Rinkos pokalbiai

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

2025-07-14 18:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-14 16:59; UTC

Rinkos pokalbiai

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

2025-07-14 16:53; UTC

Karštos akcijos

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

2025-07-14 16:27; UTC

Rinkos pokalbiai

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

2025-07-14 16:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-14 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-14 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-14 16:12; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Akcijų palyginimas

Kainos pokytis

REVOLUTION Medicines Inc Prognozė

Kainos tikslas

By TipRanks

86.43% į viršų

12 mėnesių prognozė

Vidutinis 70.88 USD  86.43%

Aukščiausias 80 USD

Žemiausias 57 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines REVOLUTION Medicines Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

9

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

40.67 / 41.96Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

148 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.